Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis

Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis

Objective. Comparative pharmacoeconomic evaluation of upadacitinib, baricitinib and dupilumab for the treatment of moderate to severe atopic dermatitis.Materials and methods. Study design — retrospective. Pharmacoeconomic analysis method — cost-effectiveness analysis, budget impact analysis. Data sou...

Full description

Bibliographic Details
Main Authors: S. K. Zyryanov, I. N. Dyakov, N. I. Ilina
Format: Article
Language:Russian
Published: Izdatelstvo OKI 2023-07-01
Series:Качественная клиническая практика
Subjects:
атопический дерматит
терапия
easi-75
easi-90
ингибиторы jak
иммунобиологические препараты
терапевтические моноклональные антитела
упадацитиниб
барицитиниб
дупилумаб
Online Access:https://www.clinvest.ru/jour/article/view/666

Similar Items

Similar Items